From flyonthewall 38 minutes ago Questcor estimates raised on Acthar prescription trends at WJB Capital WJB Capital raised its Acthar Q4 estimate to $71M from $67M, ahead of the consensus forecast of $66M, based on Acthar trends through November. WJB found today's update from Questcor as encouraging and maintains a Buy rating on the stock with a $50 price target. :theflyonthewall.com
Questcor weakness a buying opportunity, says Oppenheimer Oppenheimer believes Questcor's script update today suggests as much as $6M-$9M upside to its Acthar revenue estimate for Q4. The firm recommends adding to positions amid today's weakness and keeps an Outperform rating on the stock. :theflyonthewall